MedTrace Logo

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

NCT05260684 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 716

Last updated 2025-03-06

Study results available
· View outcomes & findings →

Summary

This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.

The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.

Conditions

Interventions

DRUG

Encorafenib

450 mg QD

DRUG

Binimetinib

45 mg BID

DRUG

Vemurafenib

960 mg BID for 28 days/cycle

DRUG

Cobimetinib

60 mg QD for 21 days/cycle

DRUG

Dabrafenib

150 mg BID

DRUG

Trametinib

2 mg QD

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05260684 on ClinicalTrials.gov